RxDoctor Payments Data

Robert Wilson, DO

Pain Medicine · Allentown, PANPI 1508854274

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.1% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Medtronic at 40.2% of the total.

$6,576in general payments, 2019–2025

Across 169 payments — averaging $38.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$962
  • Pfizer$339
  • Collegium Pharmaceutical, Inc.$314
  • Stryker$303
  • Vertos Medical, Inc.$268
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$3255%
  • Food & beverage$6,25195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,576 in reported general payments places this provider in the 80th percentile of 294 pain medicine providers in Pennsylvania.

See all pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$162,513
Medicare patients
448
Services billed
1,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl64$72,848
NucyntaTapentadol Hcl36$40,787
OxycontinOxycodone Hcl57$33,942
Xtampza ErOxycodone Myristate55$33,682
Buprenorphine76$21,857
Gabapentin452$7,277
Hysingla ErHydrocodone Bitartrate18$6,498
Pregabalin167$5,853
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen239$4,472
Tizanidine Hcl239$3,408
Morphine Sulfate ErMorphine Sulfate100$3,381
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen148$3,254
Oxycodone Hcl194$3,151
Tramadol Hcl ErTramadol Hcl35$3,001
Lidocaine25$2,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta, Xtampza Er$314$147,317155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 294 pain medicine providers in Pennsylvania.

Other pain medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →